Melatonin trial for MS halted early – what we know
NCT ID NCT03540485
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding melatonin to the standard drug ocrelizumab could safely slow disability in people with progressive primary multiple sclerosis. The trial was terminated early, so results are limited. Participants were adults aged 18–65 with this type of MS.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital Vithas Nisa Sevilla
Seville, Seville, 41950, Spain
-
Virgen Macarena Hospital
Seville, Seville, 41009, Spain
-
Virgen del Rocio University Hospital
Seville, Seville, 41013, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a blood pressure pill slow MS disability?
- Can lifestyle choices after a stroke extend life and prevent a second one?
- Strumming for the brain: could ukulele lessons sharpen minds in MS?
- Could music be medicine for the injured brain?
- Could a simple injection replace an IV for MS treatment?
- Can engineered immune cells tame autoimmune disease?